<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02297945</url>
  </required_header>
  <id_info>
    <org_study_id>HRA112025-002</org_study_id>
    <nct_id>NCT02297945</nct_id>
  </id_info>
  <brief_title>Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome</brief_title>
  <acronym>PROMPT</acronym>
  <official_title>Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HRA Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HRA Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective, international phase III/IV study is to assess the efficacy&#xD;
      and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks&#xD;
      of treatment. The ability of metyrapone (250 mg capsules) to normalize urinary free cortisol&#xD;
      (UFC) levels will be assessed during up to 36 weeks (9 months) of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will include Cushing disease patients with persistent or recurrent disease (after&#xD;
      pituitary surgery) or who are newly diagnosed but are unsuitable for early surgery or wish to&#xD;
      defer surgery. It will also include patients with ectopic ACTH syndrome (either occult, after&#xD;
      surgery failure, or inoperable or metastatic) and patients with Cushing's syndrome from&#xD;
      adrenal causes.&#xD;
&#xD;
      The ability of metyrapone to normalize urinary free cortisol levels will be assessed during&#xD;
      up to 36 weeks (9 months) of treatment. Patients participating in this study and who are&#xD;
      controlled or close to the target at the end of a 3-months period may continue with an&#xD;
      optional extension period of 6 months in which the long-term efficacy and safety profiles of&#xD;
      metyrapone will be assessed. This extension study is intended to provide new findings to&#xD;
      consolidate existing efficacy and safety data on metyrapone in the treatment of Cushing's&#xD;
      syndrome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">April 29, 2020</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalization of cortisol levels (urinary free cortisol)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cushing's Syndrome</condition>
  <arm_group>
    <arm_group_label>Metyrapone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metyrapone will be administered orally in an open-label fashion. Two possible initiation doses will be used depending on the severity of hypercortisolism, dose will then be adjusted (up or down-titrated) during the first month on an individual basis according to clinical tolerance and cortisol levels achieved.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metyrapone</intervention_name>
    <description>Single arm study</description>
    <arm_group_label>Metyrapone</arm_group_label>
    <other_name>Metopirone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Patients with endogenous Cushing's syndrome:&#xD;
&#xD;
          -  Cushing disease patients with persistent or recurrent disease (after pituitary&#xD;
             surgery) or who are newly diagnosed but are unsuitable for early surgery or wish to&#xD;
             defer surgery;&#xD;
&#xD;
          -  Patients with ectopic ACTH syndrome (either occult, after surgery failure, or&#xD;
             inoperable or metastatic);&#xD;
&#xD;
          -  Patients with Cushing's syndrome from adrenal causes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pseudo Cushing's syndrome&#xD;
&#xD;
          2. Cyclic Cushing's syndrome defined by at least one normal UFC value among at least&#xD;
             three 24-hour urinary sampling measurements over the previous 2 months&#xD;
&#xD;
          3. Advanced adrenocortical carcinoma or ectopic ACTH secretion (EAS) secondary to a small&#xD;
             cell lung carcinoma&#xD;
&#xD;
          4. Life expectancy less than 3 months&#xD;
&#xD;
          5. Pituitary or adrenal surgery or pituitary irradiation or surgery of the ACTH-secreting&#xD;
             ectopic tumor or bilateral adrenalectomy planned before the week 12 visit&#xD;
&#xD;
          6. Pituitary irradiation within the previous 5 years (for Cushing's disease patients)&#xD;
&#xD;
          7. Enlarged pituitary adenoma (greater than 1 cm in vertical diameter and leaving less&#xD;
             than 2 mm from the chiasma) or compression of the optic chiasma on the pituitary MRI&#xD;
             for patients with Cushing's disease&#xD;
&#xD;
          8. Severe uncontrolled hypertension (&gt;180/110 mmHg) despite anti-hypertensive therapy&#xD;
             (for otherwise eligible patients, blood pressure medication may be adjusted to meet&#xD;
             this criterion)&#xD;
&#xD;
          9. Severe hypokalemia (&lt; 2.5 mmol/L) despite corrective measures&#xD;
&#xD;
         10. White blood cell counts &lt;3 x 109 /L; hemoglobin &lt;10 g/dL; platelets &lt;100 x 109 /L&#xD;
&#xD;
         11. Any other severe acute or chronic medical or psychiatric condition, or laboratory&#xD;
             abnormality that in the judgment of the investigator, would present excess risk&#xD;
             associated with study participation or study drug administration, or which, in the&#xD;
             judgment of the investigator, would make the patient inappropriate for entry into this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Erasme</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital Saint Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munich university</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State health center</name>
      <address>
        <city>Budapest</city>
        <zip>10062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem II. Belgyógyászati Klinika</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Debrecen</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pecs</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Luigi Gonzaga Hospital, University of Turin</name>
      <address>
        <city>Orbassano</city>
        <state>Turin</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Luca IRCCS Istituto Auxologico Italiano</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Giuseppe Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federico II University</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Turin</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul National de Endocrinologie 'C.I Parhon' - Endocrinologie II</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul National de Endocrinologie 'C.I Parhon' - Endocrinologie VI</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Universitar de Urgenta Militar Central 'Dr Carol Davila'</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Cluj-Napoca</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Sibiu</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C Centrul Clinic Mediquest SRL</name>
      <address>
        <city>Sângeorgiu De Mureş</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean Mures</name>
      <address>
        <city>Târgu-Mureş</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Ribera</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Numune Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul UMF</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayıs University Medical Faculty</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karadeniz Teknik University</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cushing Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metyrapone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

